Prospective study of the antitumor efficacy of long‐term octreotide treatment in patients with progressive metastatic gastrinoma

Cancer - Tập 94 Số 2 - Trang 331-343 - 2002
Homayoun Shojamanesh1, Fathia Gibril1, Adeline Louie2, Jeremiah V. Ojeaburu1, Showkat Bashir1, Alaa Abou‐Saif1, Robert T. Jensen1
1Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
2Diagnostic Radiology Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland

Tóm tắt

AbstractBACKGROUNDMalignant pancreatic endocrine tumors (PETs) have a poor prognosis and existing antitumor treatments are unsatisfactory. Recent studies have shown somatostatin analogues to have antitumor growth effects in patients with malignant PETs; however, to the authors' knowledge, little information exists regarding their efficacy or effect on survival in patients with progressive malignant gastrinoma, the most common symptomatic malignant PET. The purpose of the current study was to study prospectively the efficacy, safety, and effect on survival of long‐term treatment with octreotide in consecutive patients with progressive malignant gastrinoma.METHODSFifteen consecutive patients with malignant gastrinoma with progressive hepatic metastases were studied. All patients underwent conventional imaging studies (computed tomography scan, magnetic resonance imaging, ultrasound, and, if needed, selective angiography) and somatostatin receptor scintigraphy prior to treatment and at 3–6‐month intervals while receiving treatment. The patients all were treated initially with octreotide, 200 μg every 12 hours, and at last follow‐up were being maintained on long‐acting release octreotide, 20–30 mg every month. Tumor size and/or number were used to classify patient responses as either no tumor response or tumor response (stabilization or decrease in size). Treatment response was correlated with tumor and clinical characteristics.RESULTSTumors in 8 of the 15 patients studied (53%) responded at 3 months, with 47% (7 of 15 patients) demonstrating tumor stabilization and 6% (1 of 15 patients) demonstrating a decrease in tumor size. The mean duration of response was 25.0 ± 6.1 months (range, 5.5–54.1 months). Six of the eight responders were continuing to respond at the time of last follow‐up. Tumor response did not correlate with any clinical parameter (e.g., tumor extent, fasting gastrin, or acid secretory rates). However, slow‐growing tumors were more likely to respond prior to treatment (86% vs. 0%) (P < 0.0014). During follow‐up (range, 4–8 years), 25% of the responders died compared with 71% of the nonresponders, a difference that approached statistical significance (P = 0.10). Two patients (13%) developed serious side effects that required the withdrawal of octreotide.CONCLUSIONSOctreotide is an effective antitumor treatment in patients with progressive malignant gastrinoma. In approximately 50% of these patients octreotide has an antigrowth effect; treatment is associated with a low incidence of serious side effects compared with other antitumor treatments commonly used and, in contrast to many studies, the growth response is long‐lasting. The results of the current study suggest that octreotide treatment should replace chemotherapy as the standard treatment for these patients, especially those patients with slow‐growing tumors. Additional studies involving larger numbers of patients will be needed to determine a convincing effect on survival. Cancer 2002;94:331–43. © 2002 American Cancer Society.

Từ khóa


Tài liệu tham khảo

10.1159/000051856

Jensen RT, 1999, Recent advances in pathophysiology and management of inflammatory bowel diseases and digestive endocrine tumors, 192

10.1016/S0002-9610(85)80024-6

10.1200/JCO.1999.17.2.615

10.1136/gut.43.3.422

Jensen RT, 1993, The pancreas: biology, pathobiology and disease, 931

10.1016/0016-5085(95)90124-8

10.1200/JCO.1997.15.6.2420

10.1097/00001622-199701000-00011

Fraker DL, 1997, Cancer: principles and practice of oncology, 1678

Arnold R, 1995, Endocrine tumors of the pancreas: recent advances in research and management, 431

10.1016/0016-5085(88)90670-1

10.1016/0016-5085(93)90965-F

10.1159/000051860

10.1056/NEJM199202203260804

10.1056/NEJM198011203032101

10.1002/1097-0142(19930415)71:8<2624::AID-CNCR2820710830>3.0.CO;2-B

Jensen RT, 1997, Current clinical topics in gastrointestinal pharmacology, 144

10.1016/S0959-8049(01)00073-9

10.1097/00000421-200008000-00020

10.1136/gut.39.2.279

10.1159/000051861

10.1007/978-3-642-59587-5_3

Jensen RT, 1998, 871

Jensen RT, 2001, Cancer: principles and practice of oncology, 1813

10.1136/gut.38.3.430

Zayene A, 1997, Survival factors in patients with endocrine liver metastases, Gut, 41, A184

10.7326/0003-4819-119-3-199308010-00004

10.1097/00005792-200011000-00004

10.1016/0002-9343(94)90323-9

10.7326/0003-4819-111-9-713

10.1007/BF01655106

10.1097/00005792-200105000-00005

10.1056/NEJM199908263410902

Gibril F, 1998, Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management, J Clin Oncol, 16, 1040, 10.1200/JCO.1998.16.3.1040

10.1148/radiology.198.1.8539410

10.1148/radiology.202.1.8988205

10.7326/0003-4819-125-1-199607010-00005

Jensen RT, 2001, Surgical endocrinology: clinical syndromes, 291

10.1097/00001622-200007000-00015

10.1002/(SICI)1097-0142(19981201)83:11<2293::AID-CNCR8>3.0.CO;2-E

Norton JA, 1997, Cancer: principles and practice of oncology, 1723

10.1159/000051859

Ruszniewski P, 1991, [Intravenous chemotherapy with streptozotocin and 5 fluorouracil for hepatic metastases of Zollinger‐Ellison syndrome. A prospective multicenter study in 21 patients], Gastroenterol Clin Biol, 15, 393

10.1002/bjs.1800810925

10.1111/j.1572-0241.1998.465_q.x

10.1023/A:1008205415035

10.1002/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q

Angeletti S, 1999, Single dose of octreotide stabilize metastatic gastro‐entero‐pancreatic endocrine tumours, Ital J Gastroenterol Hepatol, 31, 23

Jensen RT, 1998, Textbook of gastroenterology, 2193

10.1023/A:1008383132024

10.1159/000007693

10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4

10.1200/JCO.1999.17.4.1111

10.1136/gut.38.1.33

10.1056/NEJM200008243430805

Kvols L, 1987, Treatment of the malignant carcinoid syndrome (MCS) with a long acting somatostatin analogue (SMS 201‐995): preliminary evidence that more is not better, Proc Am Soc Clin Oncol, 6, 370

10.1007/BF01536043

10.7326/0003-4819-110-1-35

Fiasse R, 1993, Use of octreotide in the treatment of digestive neuroendocrine tumours. Seven year experience in 20 cases including 9 cases of metastatic midgut carcinoid and 5 cases of metastatic gastrinoma, Acta Gastroenterol Belg, 56, 279

10.1016/0002-9343(86)90585-1

10.1056/NEJM198609113151102

Eriksson B, 1999, Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook, Ann Oncol, 10, S31, 10.1093/annonc/10.suppl_2.S31

10.1097/00001622-200101000-00010

10.1002/(SICI)1097-0142(19970215)79:4<830::AID-CNCR20>3.0.CO;2-#

10.1056/NEJM199601253340408

10.3181/00379727-217-44216

10.1159/000049159

10.3109/02841869709001323

10.1023/A:1005774713202

Thông tin
Thông tin xuất bản

Cancer

Tập 94 Số 2

331-343

Thông tin tác giả